Zentase is a porcine-derived pancreatic enzyme replacement therapy which is being developed to treat pancreatic insufficiency.
Gearoid Faherty, CEO of Eurand, said: “We understand that the typical FDA review period of a drug with priority review status is six months versus a standard 10-month review. In the interim, we remain focused on the build-out of our US specialty sales force in preparation for the potential commercialization of Zentase.”